суббота, 20 ноября 2010 г.

Dovitinib




Lee S. H.; Lopes de Menezes, D. Vora, J. Harris, A.; Ye, H. Nordahl, L.; Garrett, E.; Samara, E.; Aukerman, S. L.; Gelb, A. B. Heise, C. In Vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models. Clin. Cancer Res. 2005, 11 (10), 3633–3641.
 
Lopes de Menezes, D. E.; Peng, J.; Garrett, E. N.; Louie, S. G.; Lee, S. H.; Wiesmann, M.; Tang, Y.; Shephard, L.; Goldbeck, C.; Oei, Y.; Ye, H.; Aukerman, S. L.; Heise, C. CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia. Clin. Cancer Res. 2005, 11 (14), 5281–5291.
Trudel, S.; Li, Z. H.; Wei, E.; Wiesmann, M.; Chang, H.; Chen, C.; Reece, D.; Heise, C.; Stewart, A. K. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005, 105 (7), 2941–2948.

Synthesis of Dovitinib
Tetrahedron Letters 47 (2006) 657–660
LHMDS mediated tandem acylation–cyclization of 2-aminobenzenecarbonitriles with 2-benzymidazol-2-yl acetates: a short and efficient route to the synthesis of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones
William R. Antonios-McCrea, Kelly A. Frazier, Elisa M. Jazan, Timothy D. Machajewski, Christopher M. McBride, Sabina Pecchi, Paul A. Renhowe, Cynthia M. Shafer and Clarke Taylor




Комментариев нет:

Отправить комментарий

Ярлыки

акситиниб (1) Бринатиниб (1) ваталаниб (1) Гефитиниб (1) гливек (1) дазатиниб (2) данусертиб (1) зактима (1) икотиниб (1) карнетиниб (1) Кризотиниб (1) куизартиниб (1) лапатиниб (1) лекарства (1) лекарство (1) линифаниб (1) Маситиниб (1) нексавар (1) понатиниб (1) руксолитиниб (1) сорафениб (1) спрайсел (2) Сунитиниб (2) сутент (1) тайверб (1) тандуниб (1) Тарцева (2) Цедираниб (1) Эрлотиниб (2) AB1010 (1) ABT-869 (1) Afatinib (2) AG-013736 (1) ALK-kinase (1) AMG-706 (1) AP24534 (1) Apatinib (1) Armala (1) AV-951 (1) axinitib (1) AZD-0530 (1) AZD2171 (2) Bafenitib (1) Bafetinib (2) BAY 73-4506 (1) BIBW 2992 (1) BMS-540215 (2) bosutinib (2) Brivanib (2) canertinib (1) Cediranib (2) CEP-701 (1) CHIR258 (1) CP690550 (1) Crizotinib (1) danusertib (1) Dasatinib (2) Dovitinib (1) Erlotinib (1) Foretinib (1) Gefinitib (1) Gefitinib (2) gleevec (1) Gold reagent (1) HKI 272 (1) Icotinib (1) imatinib (1) INNO-406 (2) Iressa (1) lapatinib (2) lestaurtinib (1) linifanib (1) Masitinib (1) MLN 518 (1) Mubritinib (2) Nexavar (2) nilotinib (1) NS-187 (2) OSI-774 (1) Palladia (1) Pazopanib (2) Pelitinib (1) PF-02341066 (1) PHA-739358 (1) Ponatinib (1) pyrazole (1) Recentin (2) Regorafenib (1) Ruxolitinib (1) Saracatinib (2) sc-202353 (1) Silimitasertib (1) SKI-606 (2) Sorafenib (2) Sorafenib tosylate (1) Sprycel (2) Sunitinib (2) Sunitinib Malate (2) Sutent (2) Tarceva (2) targeted agents (1) tasigna (1) Tasocitinib (1) Tivozanib (1) TKI-258 (1) toceranib (1) Tovok (2) tykerb (2) tyverb (1) vandetanib (1) Vatalanib (1) Votrient (2) YN968D1 (1) zactima (1) ZD6474 (1) 凡德他尼 (1) 尼罗替尼 (1) 阿西替尼 (1)